A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.

Giulia MarelliLouisa S Chard DunmallMing YuanCarmela Di GioiaJinxin MiaoZhenguo ChengZhongxian ZhangPeng LiuJahangir AhmedRathi GangeswaranNicholas LemoineYaohe Wang

Published in: Journal for immunotherapy of cancer (2021)

Intravenously administered VVL-21 successfully remodeled the suppressive tumor-microenvironment to promote antitumor immune responses and improve long-term survival in animal models of pancreatic cancer. Importantly, treatment with VVL-21 sensitized tumors to the immune checkpoint inhibitor α-PD1. Combination of PI3Kδ inhibition, VVL-21 and α-PD1 creates an effective platform for treatment of pancreatic cancer.

Keyphrases

immune response
dendritic cells
high throughput
combination therapy
toll like receptor